TRAIL, Fas Ligand, TNF and TLR3 in Cancer

1. Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer
Jessica Wagner, Christina Leah Kline, Wafik El-Deiry

2. TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer
Lubna Danish, Daniela Stöhr, Peter Scheurich, Nadine Pollak

3. IAPs and Resistance to Death Receptors in Cancer
Laurence Dubrez, Simone Fulda

4. Bcl-2 Proteins and TRAIL Resistance in Melanoma
Jürgen Eberle

5. Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4
James Sledziona, Vivek M. Rangnekar

6. Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy
Andrea Mohr, Ralf Zwacka

7. Atypical Immune Functions of CD95/CD95L
Amanda Poissonnier, Patrick Legembre

8. TLR3 Is a Death Receptor Target in Cancer Therapy
Yann Estornes, Toufic Renno, Serge Lebecque

9. Fas/CD95, Lipid Rafts, and Cancer
Faustino Mollinedo, Consuelo Gajate

10. Role of Sphingolipids in Death Receptor Signalling
Fatima Bilal, Michaël Pérès, Nathalie Andrieu-Abadie, Thierry Levade, Bassam Badran, Ahmad Daher, Bruno Ségui

11. Posttranslational Modifications and Death Receptor Signalling
Olivier Micheau

12. System Modeling of Receptor-Induced Apoptosis
François Bertaux, Dirk Drasdo, Grégory Batt

Nyckelord: Biomedicine, Cancer Research